T cell Immunoglobulin and Mucin Domain Containing Protein 3 (TIM-3) Inhibitors in Oncology Clinical Trials: A Review
Journal of Immunotherapy and Precision Oncology · 01.05.2024 · 7 (2) · 89-96
DOI: 10.36401/jipo-23-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Immunotherapy and Precision Oncology, online erschienen am 02.05.2024. Verfasst von Benjamin Duong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Sarah Cannon Research Institute at HealthONE, Denver, CO, USA. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
T cell immunoglobulin and mucin domain containing protein 3 (TIM-3) is a receptor found on a multitude of immune cells and is commonly overexpressed in patients with cancer. Due to its selective expression in immune cells and its preliminary efficacy in preclinical models, TIM-3 is a promising target as a treatment for cancer. Both monotherapy and combination regimens are being developed and are currently under investigation. This clinical review seeks to summarize and compile past, present, and future TIM-3 inhibitors in clinical trials.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sarah Cannon Research Institute at HealthONE, Denver, CO, USA.
ORCID-Profile: Gerald S Falchook
Zitieren
APA
Duong, B., Banskota, P., & Falchook, G. S. (2024). T cell Immunoglobulin and Mucin Domain Containing Protein 3 (TIM-3) Inhibitors in Oncology Clinical Trials: A Review. Journal of Immunotherapy and Precision Oncology, 7(2), 89-96. https://doi.org/10.36401/jipo-23-4
Vancouver
Duong B, Banskota P, Falchook GS. T cell Immunoglobulin and Mucin Domain Containing Protein 3 (TIM-3) Inhibitors in Oncology Clinical Trials: A Review. Journal of Immunotherapy and Precision Oncology. 2024;7(2):89-96. doi:10.36401/jipo-23-4
BibTeX
@article{Duong2024,
author = {Duong, Benjamin and Banskota, Pratyush and Falchook, Gerald S},
title = {T cell Immunoglobulin and Mucin Domain Containing Protein 3 (TIM-3) Inhibitors in Oncology Clinical Trials: A Review},
journal = {Journal of Immunotherapy and Precision Oncology},
year = {2024},
volume = {7},
number = {2},
pages = {89--96},
doi = {10.36401/jipo-23-4}
}
EUVIMED